Jiedu Huayu Oral Prescription in the Treatment of Intracranial Hemorrhage Associated With Cerebral Amyloid Angiopathy

Recruiting now · Phase 3 · Has a placebo group

Conditions studied: Cerebral Amyloid Angiopathy

In brief

Cerebral hemorrhage, as a serious cerebrovascular disease, has the highest disability rate and mortality rate among all types of cerebrovascular diseases .It has brought a heavy burden to society. In China, the incidence of cerebral hemorrhage is much higher than that in Europe and America, and cerebral amyloid angiopathy (CAA) is one of the causes of primary cerebral hemorrhage However, there are relatively few related studies. Therefore, the research object of this subject focuses on patients with cerebral amyloid angiopathy, in view of their high recurrence rate of vascular events and the lack of treatment methods.It aims to deeply explore the detoxification and blood stasis removal treatment plan combining traditional Chinese and Western medicine to reduce vascular events for patients.

Key facts

Study ID

NCT07250035

Run by

Beijing Tiantan Hospital

People needed

436

Starts

2026-01-30

Expected to finish

2028-11-30

Last updated by the study team

2026-06-24

Who can join

Age: 50 and older, up to 90. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• ① Possible or very likely CAA-ICH;
• Within 7 days of onset; ③ Primary supratentorial intracerebral hemorrhage (bleeding volume ≤40ml);
• GCS≥8 points;
• NIHSS score ≤25 points; ⑥50≤age≤90 years old; ⑦ Gender is not limited; ⑧ The subject or their legal representative gives informed consent and signs the informed consent form.

You may not qualify if…

• Those who are known to be allergic to the components of the traditional Chinese medicine compound used in the experiment;
• It is known that after treatment with vascular malformations, aneurysms, coagulation disorders, anticoagulant or antiplatelet drugs, Intracranial conditions caused by clear etiologies such as thrombolytic therapy, post-infarction hemorrhage transformation, hematological diseases, moyamoya disease, etc;
• Patients with traumatic intracranial hemorrhage;
• Patients with active peptic ulcers or other clear tendencies of rebleeding;
• Patients with severe liver or kidney dysfunction (Note: Severe liver dysfunction is defined as ALT or AST being greater than.
• ⑥ Those who have received or are planning to undergo surgical treatment;
• ⑦ Those who suffer from other life-threatening serious diseases and have an expected survival time of less than six months;
• ⑧ Other conditions that significantly limit the evaluation of neurological function, prevent the completion of cranial magnetic resonance imaging, or affect the follow-up of patient;
• ⑨ Pregnant women, those planning to become pregnant or lactating women;
• ⑩Those who are currently participating in other interventional clinical trials.

Where it is running

• Beijing Tiantan Hospital, Capital Medical University — Beijing, China (enrolling)

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.